IBEC researchers Benedetta Bolognesi, Xavier Fernàndez Busquets and Xavier Trepat have been selected in the CaixaResearch 2024 call to lead their own research projects. The grants will provide financial support for the scientists to carry out their research in key areas such as cancer, malaria and amyotrophic lateral sclerosis.
A study led by IBEC and ISGlobal has demonstrated the antileishmanial potential of an antimalarial compound. Initially designed for malaria, this drug shows high efficacy against leishmaniasis, representing a unique and promising breakthrough for the treatment of both infections.
Introduction to the vacant position: The Nanomalaria Group is looking for an Early Stage Researcher (PhD student) to develop his/her PhD thesis project on the development of new antimalarial drugs. … Read more
According to the study, the strategy has the added advantage of targeting the transmissible phase of the parasite- the gametocyte. Encapsulating two drugs with different properties into nanovesicles surrounded by antibodies can greatly improve their delivery and efficacy, according to a study led by Xavier Fernández Busquets, director of the joint Nanomalaria unit at the Institute for Bionengineering of Catalonia (IBEC) and the Barcelona Institute for Global Health (ISGlobal), an institution supported by ”la Caixa”. Combining two drugs that act through different mechanisms is one of the most efficient approaches currently used to treat malaria. However, differences in the drugs’ physichochemical properties (solubility, half-life, etc.) often affect treatment efficacy.
The Institute for Bioengineering of Catalonia (IBEC), the Barcelona Institute for Global Health (ISGlobal) and the biotech firm Bioiberica have signed a partnership agreement to study the development of new compounds derived from heparin to combat malaria. The partnership, which was officially announced this morning at the BioSpain meeting in Bilbao, is based on the research undertaken by Dr Xavier Fernández-Busquets, head of IBEC and ISGlobal’s joint Nanomalaria unit, engaged in developing specific antimalaria therapies, and the R&D project of Bioiberica, world leader in heparin production, to seek new applications of this molecule.
Every year malaria infects 200 million people worldwide and causes half a million deaths. For several decades it has been known that when the malaria parasite enters the bloodstream, it invades the liver cells to produce thousands of merozoites – a stage in the life cycle of the parasite – that enter into the circulation and infect red blood cells, managing to evade the immune system.